Agilent Technologies Acquires Biocare Medical, Expanding Pathology Portfolio
Agilent Technologies announced the completion of its acquisition of Biocare Medical, a leader in clinical pathology solutions. The deal is expected to enhance Agilent's product offerings and contribute to growth.
Agilent Technologies Inc. announced on June 25, 2026, the successful completion of its acquisition of Biocare Medical. Biocare Medical is recognized as a global leader in clinical pathology, specializing in immunohistochemistry and molecular pathology solutions.
The integration of Biocare Medical into Agilent's Life Sciences and Diagnostics Markets Group is expected to strengthen the company's position in the pathology market. Agilent President and CEO Padraig McDonnell stated that the acquisition is a strategic expansion, enhancing the company's ability to serve customers across both clinical and research settings.
Agilent anticipates that the transaction will be accretive to its topline growth rate, margin profile, and non-instrument revenue mix within the first year. Furthermore, the acquisition is projected to become accretive to Agilent's earnings per share approximately 12 months after closing. Specific impacts on Agilent's fiscal year 2026 financial results will be detailed in the third-quarter earnings release.
Biocare Medical's offerings include automated instrumentation, high-quality reagents, and simultaneous multiplexing capabilities, aimed at advancing cancer diagnostics. This acquisition is set to deepen Agilent's expertise and broaden its capacity to support pathology customers worldwide.